Middle Molecules: Toxicity and Removal by Hemodialysis and Related Strategies
- 12 November 1995
- journal article
- review article
- Published by Wiley in Artificial Organs
- Vol. 19 (11) , 1120-1125
- https://doi.org/10.1111/j.1525-1594.1995.tb02273.x
Abstract
Renal failure results in the retention of metabolites which may arbitrarily be grouped according to their molecular weight: low ( 15, 000 daltons). Opinion in respect to the relative importance of these groups varies. Initially it was thought that small molecules were important. In the mid‐1970s, investigators identified the possible pathophysiological role of middle molecules. However, since positive identification of such molecules was difficult, opinion has shifted back in favor of small molecules, and little attention, with the exception of β2 microglobulin, has been paid to middle molecules and their removal by hemodialysis and related therapies. In this review current knowledge regarding middle molecules identified as uremic toxins and their removal by hemodialysis and associated therapies are discussed.Keywords
This publication has 41 references indexed in Scilit:
- Microtiter plate assay for phagocyte‐derived Taurine‐chloraminesJournal of Clinical Laboratory Analysis, 1992
- Plasma endothelin levels in hypertension and chronic renal failure.Hypertension, 1990
- Verapamil reverses PTH- or CRF-induced abnormal fatty acids oxidation in muscleKidney International, 1988
- Immunomodulating properties of the uremic pentapeptide H-Asp-Leu-Trp-Glu-Lys-OH in vitroJournal of Molecular Medicine, 1986
- HAEMODIALYSIS MEMBRANES, SERUM β2-MICROGLOBULIN, AND DIALYSIS AMYLOIDOSISThe Lancet, 1986
- Calcitonin gene-related peptide is a potent vasodilatorNature, 1985
- Effect of Parathyroid Hormone on Osmotic Fragility of Human ErythrocytesJournal of Clinical Investigation, 1982
- Effect of the Hemodialysis Prescription on Patient MorbidityNew England Journal of Medicine, 1981
- Effect of parathyroid hormone on erythropoiesis.Journal of Clinical Investigation, 1981
- Serum β2-Microglobulin in Hemodialyzed PatientsNephron, 1978